FDA Fluvirin Inspections Focusing On Readiness For 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
"Ongoing FDA investigation" is looking at "manufacturing quality systems related to assuring sterility of final vaccine product," agency says. Pledge to cooperate with British authorities may signal truce on regulatory finger pointing.
You may also be interested in...
Chiron Fluvirin Remediation Plan Design Underway
The four-pronged plan will address “bio-burden,” manufacturing techniques, quality systems and execution, CEO Pien says. Chiron has met twice with U.K. authorities and hopes to realize similar progress with FDA soon.
Chiron Fluvirin Remediation Plan Design Underway
The four-pronged plan will address “bio-burden,” manufacturing techniques, quality systems and execution, CEO Pien says. Chiron has met twice with U.K. authorities and hopes to realize similar progress with FDA soon.
Chiron Submits NDA For Inhaled Immunosuppressant Pulminiq For Lung Transplant
The company has requested priority review for the aerosolized cyclosporine product for chronic lung transplant rejection. The Oct. 14 NDA is limited to chronic rejection because pivotal study failed to show significance for acute rejection.